Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS

M. Kaisrlikova, J. Vesela, D. Kundrat, H. Votavova, M. Dostalova Merkerova, Z. Krejcik, V. Divoky, M. Jedlicka, J. Fric, J. Klema, D. Mikulenkova, M. Stastna Markova, M. Lauermannova, J. Mertova, J. Soukupova Maaloufova, A. Jonasova, J. Cermak,...

. 2022 ; 36 (7) : 1898-1906. [pub] 20220503

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22025348

Patients with lower-risk myelodysplastic syndromes (LR-MDS) have a generally favorable prognosis; however, a small proportion of cases progress rapidly. This study aimed to define molecular biomarkers predictive of LR-MDS progression and to uncover cellular pathways contributing to malignant transformation. The mutational landscape was analyzed in 214 LR-MDS patients, and at least one mutation was detected in 137 patients (64%). Mutated RUNX1 was identified as the main molecular predictor of rapid progression by statistics and machine learning. To study the effect of mutated RUNX1 on pathway regulation, the expression profiles of CD34 + cells from LR-MDS patients with RUNX1 mutations were compared to those from patients without RUNX1 mutations. The data suggest that RUNX1-unmutated LR-MDS cells are protected by DNA damage response (DDR) mechanisms and cellular senescence as an antitumor cellular barrier, while RUNX1 mutations may be one of the triggers of malignant transformation. Dysregulated DDR and cellular senescence were also observed at the functional level by detecting γH2AX expression and β-galactosidase activity. Notably, the expression profiles of RUNX1-mutated LR-MDS resembled those of higher-risk MDS at diagnosis. This study demonstrates that incorporating molecular data improves LR-MDS risk stratification and that mutated RUNX1 is associated with a suppressed defense against LR-MDS progression.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22025348
003      
CZ-PrNML
005      
20240104140921.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41375-022-01584-3 $2 doi
035    __
$a (PubMed)35505182
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kaisrlikova, Monika $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/http://orcid.org/0000000188407654
245    10
$a RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS / $c M. Kaisrlikova, J. Vesela, D. Kundrat, H. Votavova, M. Dostalova Merkerova, Z. Krejcik, V. Divoky, M. Jedlicka, J. Fric, J. Klema, D. Mikulenkova, M. Stastna Markova, M. Lauermannova, J. Mertova, J. Soukupova Maaloufova, A. Jonasova, J. Cermak, M. Belickova
520    9_
$a Patients with lower-risk myelodysplastic syndromes (LR-MDS) have a generally favorable prognosis; however, a small proportion of cases progress rapidly. This study aimed to define molecular biomarkers predictive of LR-MDS progression and to uncover cellular pathways contributing to malignant transformation. The mutational landscape was analyzed in 214 LR-MDS patients, and at least one mutation was detected in 137 patients (64%). Mutated RUNX1 was identified as the main molecular predictor of rapid progression by statistics and machine learning. To study the effect of mutated RUNX1 on pathway regulation, the expression profiles of CD34 + cells from LR-MDS patients with RUNX1 mutations were compared to those from patients without RUNX1 mutations. The data suggest that RUNX1-unmutated LR-MDS cells are protected by DNA damage response (DDR) mechanisms and cellular senescence as an antitumor cellular barrier, while RUNX1 mutations may be one of the triggers of malignant transformation. Dysregulated DDR and cellular senescence were also observed at the functional level by detecting γH2AX expression and β-galactosidase activity. Notably, the expression profiles of RUNX1-mutated LR-MDS resembled those of higher-risk MDS at diagnosis. This study demonstrates that incorporating molecular data improves LR-MDS risk stratification and that mutated RUNX1 is associated with a suppressed defense against LR-MDS progression.
650    _2
$a nádorová transformace buněk $x genetika $x metabolismus $7 D002471
650    _2
$a protein PEBP2A2 $x genetika $x metabolismus $7 D050676
650    _2
$a lidé $7 D006801
650    12
$a akutní myeloidní leukemie $x genetika $7 D015470
650    _2
$a mutace $7 D009154
650    12
$a myelodysplastické syndromy $x patologie $7 D009190
650    _2
$a prognóza $7 D011379
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Vesela, Jitka $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/http://orcid.org/0000000215856763
700    1_
$a Kundrat, David $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/http://orcid.org/0000000347701229
700    1_
$a Votavova, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Dostalova Merkerova, Michaela $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $1 https://orcid.org/http://orcid.org/0000000263459180
700    1_
$a Krejcik, Zdenek $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Divoky, Vladimir $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $1 https://orcid.org/http://orcid.org/000000030202245X
700    1_
$a Jedlicka, Marek $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $u Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Fric, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $u International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic
700    1_
$a Klema, Jiri $u Czech Technical University, Prague, Czech Republic
700    1_
$a Mikulenkova, Dana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Stastna Markova, Marketa $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Lauermannova, Marie $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Mertová, Jolana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic $7 xx0312296
700    1_
$a Soukupova Maaloufova, Jacqueline $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Jonasova, Anna $u First Department of Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $1 https://orcid.org/http://orcid.org/0000000302461524
700    1_
$a Cermak, Jaroslav $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Belickova, Monika $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. monika.belickova@uhkt.cz $u First Faculty of Medicine, Charles University, Prague, Czech Republic. monika.belickova@uhkt.cz $1 https://orcid.org/http://orcid.org/000000029158881X
773    0_
$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 36, č. 7 (2022), s. 1898-1906
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35505182 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20240104140916 $b ABA008
999    __
$a ok $b bmc $g 1854856 $s 1176638
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 36 $c 7 $d 1898-1906 $e 20220503 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
LZP    __
$a Pubmed-20221017

Find record

Citation metrics

Archiving options